Related Experiment Videos
Pseudothrombocytopenia. In vitro studies on the underlying mechanism
Scandinavian Journal of Haematology
|May 1, 1981
Summary
Pseudothrombocytopenia, a spuriously low platelet count, occurs due to immune complexes interacting with platelet receptors. Using citrate-based anticoagulants reduces platelet agglutination, improving accurate thrombocyte counts.
Area of Science:
- Immunology
- Rheumatology
- Hematology
Background:
- Pseudothrombocytopenia is a condition characterized by spuriously low platelet counts.
- Accurate platelet counting is crucial for diagnosing and managing various medical conditions.
Purpose of the Study:
- To investigate the mechanisms underlying pseudothrombocytopenia.
- To identify factors influencing platelet agglutination in pseudothrombocytopenia.
Main Methods:
- Prospective study of 10 patients with pseudothrombocytopenia.
- In vitro analysis of platelet agglutination using different anticoagulants (K2EDTA vs. ACD).
- Investigation of immune complex interaction with platelet Fc receptors using Fab'2 fragments.
Main Results:
- Platelet agglutination was significantly reduced when using citrate-based anticoagulants (ACD) compared to K2EDTA.
- Circulating immune complexes interacting with platelet membrane Fc receptors were identified as a key mechanism in pseudothrombocytopenia.
- Absence of reaction between patient IgG Fab'2 fragments and normal donor thrombocytes indicated no true antiplatelet antibody activity.
Conclusions:
- Pseudothrombocytopenia can be mitigated by employing citrate-based anticoagulants for blood collection.
- Immune complex-mediated platelet aggregation, rather than true antiplatelet antibodies, is the primary cause of pseudothrombocytopenia in these patients.